Dr. Zakharia on phase 2 study of durvalumab and RT in urothelial cancer

Yousef Zakharia, MD, discusses the design and results of a phase 2 trial that explored concurrent treatment with radiation and the PD-L1 inhibitor durvalumab (Imfinzi) followed by adjuvant durvalumab in patients with urothelial cancer. Zakharia is clinical associate professor of internal medicine at the University of Iowa, Holden Comprehensive Cancer Center.